Dismeno is an herbal product containing Predimenol, a standardized extract from Phaleria macrocarpa. Predimenol is clinically proven to help reduce pain symptoms associated with endometriosis and dysmenorrhea. It has been extensively studied in both preclinical and clinical trials. These studies have consistently demonstrated the safety and effectiveness of Predimenol as a treatment for symptoms related to endometriosis and dysmenorrhea.
Dismeno contains a precisely formulated dose of 100 mg of Predimenol in capsule form.
A Brief Introduction to Our Product
DLBS1442 exerts its effect on dysmenorrhea and endometriosis by inhibiting angiogenesis and cell migration. It downregulates the estrogen receptor while upregulating the progesterone receptor. Furthermore, it suppresses the gene expressions of COX-2 and cPLA-2. DLBS1442 inhibits the eicosanoid signaling pathway by reducing the NF-кB transcription level and reducing inducible nitric oxide synthase.
Additionally, DLBS1442 leads to the downregulation of VEGF and HIF-1α, suggesting that it inhibits the transcriptional activity of HIF-1α and further reduces both cellular and secreted VEGF levels. Therefore, it can be concluded that DLBS1442 exerts its antiangiogenic activity by disturbing the binding of HIF-1α to the VEGF promoter.
Our results also demonstrated that MMP-9, which significantly impacts endometriotic lesions, is downregulated by DLBS1442. Moreover, DLBS1442 inhibits the migration of cells from one site to another and decreases COX-2 transcription levels. DLBS1442 was able to induce a cellular death signal. In light of these properties, DLBS1442 can be used as a potential treatment for decreasing the occurrence of PMS and dysmenorrhea.
Product Functions
DLBS1442 was studied preclinically to evaluate its effectiveness for treating endometriosis. The research focused on key biological processes contributing to dysmenorrhea and endometriosis, including angiogenesis, cell migration, estrogen and progesterone receptor levels, the eicosanoid pathway, cell viability, and apoptosis.
In vitro studies demonstrated that DLBS1442 downregulates the transcriptional level of HIF-1α, leading to the reduction in both cellular and secreted levels of VEGF. This reduction results in the inhibition of angiogenesis by disrupting the binding of HIF-1α to the VEGF promoter. Additionally, DLBS1442 downregulates MMP-9 activity, which prevents the breakdown of the extracellular matrix (ECM) and further inhibits cell migration. The effectiveness of DLBS1442 in inhibiting cell migration was also confirmed in RL95-2 cells through a wound closure assay, which showed a significant reduction in cell migration following treatment.
Furthermore, DLBS1442 exhibited anti-inflammatory effects by decreasing the expression of COX-2, cytosolic cPLA2, and iNOS, which is linked to the reduction of transcriptional activity of NF-κB. Moreover, DLBS1442 induced a cellular death signal, triggering apoptosis in the treated cells.
Our clinical study involving 23 individuals examined the effects of treatment on various premenstrual symptoms, focusing on menstrual cycles that ranged from 21 to 32 days, with bleeding durations of 3 to 7 days. Subjects self-assessed their symptoms using a 100-mm visual analog scale (VAS) for issues such as abdominal pain, breast tenderness, headache, and mood disturbances. Participants reported significant reductions in abdominal and back pain during the treatment period compared to the control period. Those experiencing moderate or moderate-to-severe symptoms showed remarkable decreases in breast tenderness, and improvements were noted in myalgia and headaches as well. Fatigue, nausea, and overeating symptoms also improved, although the reduction in nausea wasn't clinically significant.
Furthermore, feelings of tension, unhappiness, and difficulty concentrating showed meaningful improvement during the treatment. The safety profile reported few mild adverse events, with four subjects experiencing dyspepsia potentially linked to the treatment's mechanism that selectively inhibits cyclooxygenase-2. Overall, the study indicated effective relief from PMS symptoms and a favorable safety profile.
Insights and Discoveries
Dosage Instructions
3 times daily, but can be customized following your doctor’s instructions.
If You Miss a Dose
Take it as soon as you remember. If it's almost time for your next dose, skip the missed one. Do not take extra medicine to make up the missed dose.
Contraindications
Patients who have hypersensitivity toward this component.
Side Effects
No side effects have been reported. Considered as safe if taken at the recommended dosage.
Special warnings and precautions for use
Always tell your doctor/pharmacist if you take other medicine or food supplements.
Always tell your doctor/pharmacist if you have any allergies.
Women should tell their doctor/pharmacist if they are pregnant or planning to get pregnant
Recommendations for Safe Administration and Use of Our Product
This product is protected by a patent that is distributed across Asia.
Our Patent Rights
Store at a temperature below 30°C, in a dry place, and protect from direct sunlight.
Kept out of reach of children.
Storage Conditions
Not yet available overseas
[Dismeno can be found in global markets soon!]
Explore Our Global Markets
Anti-inflammatory, antiangiogenic, and apoptosis-inducing activity of DLBS1442, a bioactive fraction of Phaleria macrocarpa, in a RL95-2 cell line as a molecular model of endometriosis
Anti-inflammatory Effect of Predimenol, A Bioactive Extract from Phaleria macrocarpa, through the Suppression of NF-κB and COX-2
Symptomatic treatment of premenstrual syndrome and/or primary dysmenorrhea with DLBS1442, a bioactive extract of Phaleria macrocarpa